Why Is HIMS & HERS HEALTH I A (HIMS) Stock Down Today?

Hims & Hers Health shares fell 11.77% to $22.94, driven by a third-quarter earnings report that missed estimates on both revenue and earnings per share. The company also narrowed its full-year 2026 revenue guidance, citing margin pressure, which weighed on investor sentiment.

What Happened

Hims & Hers reported third-quarter revenue of $890.3 million, missing the consensus estimate of $892.9 million. GAAP earnings per share came in at negative $0.14, missing the estimate by $0.20. The company narrowed its fiscal 2026 sales guidance from a previous range of $3.1 billion to $3.3 billion to a new range of $3.13 billion to $3.15 billion. This new midpoint of $3.14 billion was below the analyst estimate of $3.209 billion. Additionally, the company provided a fourth-quarter sales outlook of $875 million to $895 million, which was significantly lower than the estimate of $953.4 million.

The stock had already declined 11.3% over the previous eight sessions, falling from $29.32 to $26.00. The latest results confirmed a trend of contracting margins. A Form 8-K filed on November 9, 2026, also disclosed the departure of certain officers or directors. Dr. Andrew Huberman was announced as a new board member, but the financial miss dominated the narrative.

What The Data Shows

The stock opened at $25.34, a 2.5% gap down from the prior close of $26.00. It hit a session high of $25.67 at 9:30 AM ET before sliding to a low of $20.63 at 4:05 PM ET. Trading volume reached 42.5 million shares, which is 3.6 times the three-month daily average. The stock printed 21 fresh 52-week lows on November 9, 2026.

Fundamentals show a market cap of $6.1 billion with a trailing twelve-month EPS of negative $0.62. Revenue grew 28.0% year-over-year, but the net margin is negative 5.5%. The stock has a beta of 2.50 and trades within a 52-week range of $13.74 to $44.00. Insider activity has been bearish, with 14 sells totaling $6.0 million in the last 90 days and no buys. Notable sales include those by General Counsel Boughton Soleil and Chief Financial Officer Okupe Oluyemi. Unusual options activity included 16 notable prints, with call premium of $4.2 million exceeding put premium of $2.1 million.

What To Watch

Investors will monitor the company's ability to execute on its narrowed fiscal 2026 guidance amid continued margin pressure. The stock's high beta and recent 52-week lows suggest heightened volatility as the market digests the weaker outlook.